India is set to launch its first indigenously developed Quadrivalent Human Papillomavirus Vaccine (qHPV) against Cervical cancer with the help of the Serum Institute of India (SII) and the Department of Biotechnology (DBT) on 1st September 2022. The vaccine for Cervical cancer “CERVAVAC”, will be launched by Union Minister of State Science and Technology Jitendra Singh. The vaccine is likely to cost around 200-400 per dose.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
As per the government data, cervical cancer ranks number 2 for most prevalent cancer in India and also accounts for one-fourth of the world’s cervical cancer deaths. Approximately 1.25 lakhs women are diagnosed with Cervical cancer and over 75 thousand females die from the disease in India. The Union government plans to target the age of 9-14 years of girls for vaccination against cervical cancer. Before the rollout of the vaccine, a sensitization program will be organized by the government to educate parents and school authorities. The government also said that CERVAVAC is an outcome of the partnership of DBT and BIRAC with the Bill and Melinda Gates Foundation.
The Gujarat Chief Minister Bhupendra Patel has made an announcement about awarding the Vishisht Gujarat…
Reserve Bank of India has granted approval for the appointment of Anup Kumar Saha as…
Governor Gavin Newsom has approved the Assembly Bill 1267 (AB 1267), which bans child marriage…
The manufacturing sector in India saw a pick-up in September 2026, as the HSBC India…
Narendra Bhooshan, who is the 1992-batch of Indian Administrative Service (IAS) from the Uttar Pradesh…
Indian batsman Rohit Sharma crossed the 12,000 ODI runs mark in the second ODI match…